Grove Biopharma develops Precision-Linked Proteomimetics™ (PLPs), a customizable class of synthetic biologics designed to target intracellular protein-protein interactions in oncology, chronic inflammatory, and neurodegenerative diseases. The platform addresses significant unmet medical needs by providing researchers access to novel drug candidates and materials science solutions for peptide therapeutic challenges.
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Intracellular protein-protein interactions (PPIs) are key drivers of many diseases, including cancer, neurodegenerative disorders, and chronic inflammatory conditions, but are difficult to target with traditional therapeutic modalities due to challenges in cell penetration and effective engagement of large PPI target domains. Current treatment options often lack the ability to selectively disrupt or degrade disease-causing target proteins within the cell.
Solution
Grove Biopharma is developing Bionic Biologics™, a class of customizable, synthetic biologics designed to target intracellular PPIs. This platform generates cell-permeable, protein-like polymers (PLPs) that can disrupt or degrade disease-causing target proteins. The modular design and tunable properties of Bionic Biologics™ enable the rapid design and development of molecules against any target, including those previously considered "undruggable." Grove's approach offers a protein-scale solution to protein-scale problems, with the potential to address a wide range of diseases driven by dysregulated intracellular PPIs.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing novel therapeutics for oncology, neurodegenerative diseases, and chronic inflammatory conditions, as well as patients living with these diseases.
Features
- Precision-Linked Proteomimetics™ (PLPs) platform for generating synthetic biologics
- Bionic Biologics™ that integrate biologic and synthetic design for enhanced functionality
- Cell-permeable molecules capable of reaching intracellular targets
- Customizable, modular construction for rapid design and development against any target
- Ability to disrupt or degrade disease-causing target proteins
- Targeting of specific protein isoforms and structural motifs
- Potential for combination therapies with existing treatments